The 10th Ocular Diseases Drug Discovery Conference is taking place on March 20-21, 2018 in San Diego, CA. We are excited to have top representatives from the industry and academic sectors to discuss technologies and targets that are continually changing the way ocular diseases are treated. Drug delivery is always improving as we look at for better methods to penetrate anterior and poster segments of the eye. Successes in gene therapy and regenerative medicine are proving to be interesting approaches to discuss in detail pre-clinically and clinically. We are gathering leading scientists, researchers, and experts to discuss and collaborate on combating and curing age-related macular degeneration (AMD), dry eye, glaucoma, diabetic macular edema (DME), and other ocular diseases.
- Opening Keynote Session: Historical Perspective and State of the Industry
- Preclinical Development of Novel Technologies
- Translational Studies and Lessons Learned
- Partnering between Industry, Academia and CROs to Advance Research
- Panel on Funding
- Panel on Regulatory Challenges
- Start-Up Showcase (Lunch Session)
- Closing Keynote Session: Predictions for Future
We hope to see you there!
The 2018 Advisory Committee
|2018 ADVISORY BOARD MEMBERS|
|Matthias Birkhoff, Aptar|
|Oscar Cuzzani, BioTime|
|Emmett Cunningham, Clarus Ventures|
|Rafal Farjo, EyeCRO LLC|
|Rangaramujam Kannan, John Hopkins University|
Powered Research, LLC is a preclinical CRO that specializes in non-GLP swine, rabbit, and rodent models in the ophthalmic space. With our extensive expertise and quick turn-around time, we've helped multiple ocular companies with their R&D needs. In addition to in-life studies, we provide full bioanalytical and histology services in-house.
CBSET is a not-for-profit translational research institute specializing in the evaluation of drugs, biotherapeutics, combination products, and medical devices. We provide preclinical services including in-life testing, histopathology and regulatory consulting. Our GLP-compliant facilities host a multidisciplinary team of medical, scientific and regulatory experts who actively collaborate in getting novel technologies to market.
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.